HLX17
Fosun Pharma Advances HLX17 and SAF-189: Strengthening Global and Domestic Oncology Footprints
hanghai Fosun Pharmaceutical is making strides in oncology with FDA approval for phase 1 trials of HLX17, a PD-1 biosimilar, and NMPA approval for phase 3 trials of SAF-189, an ALK/ROS1 inhibitor.